Alcohol Use Disorder Medications Overview
Four medications are FDA-approved for alcohol use disorder. Two more are commonly used off-label. Despite this, only about 7 percent of people with AUD in the United States ever receive medication for it. The mismatch between effective tools and clinical practice is the largest gap in addiction treatment, full stop.
| Medication | Mechanism | Dosing | Cost (cash) | Best for |
|---|---|---|---|---|
| Vivitrol | Opioid antagonist | Monthly IM | ~$1,500/shot | Reducing heavy drinking; adherence-challenged patients |
| Oral naltrexone | Opioid antagonist | Daily 50mg | $30-$80/month | Highly motivated patients with daily routine |
| Acamprosate | Glutamate/GABA modulator | 333mg x 3 daily (9 pills) | $80-$200/month | Maintaining abstinence post-detox |
| Disulfiram | Aldehyde dehydrogenase inhibitor | Daily 250-500mg | $30-$100/month | Patients with strong external accountability |
| Topiramate (off-label) | GABA/glutamate modulator | Daily titrated | $30/month generic | Comorbid AUD + migraine or epilepsy |
| Gabapentin (off-label) | GABA modulator | Daily titrated | $10-$40/month | AUD with anxiety or sleep issues |
Why so few patients get medication
Three reasons, none of them clinical. Stigma in the recovery community against medication-assisted approaches. Insufficient prescriber training in addiction medicine, especially in primary care. The myth that "just go to AA" works for everyone. None of these is a clinical reason. All of them produce undertreatment.
The two evidence-based first-line options
Naltrexone (oral or Vivitrol) and acamprosate are the two first-line medications recommended in essentially every clinical guideline. They work through different mechanisms and many patients benefit from one but not the other.
Naltrexone is best for patients whose drinking is reward-driven. They drink to feel something. Naltrexone weakens the reward signal, so the second drink is less appealing than it used to be. Heavy drinking days drop. Some patients keep drinking on naltrexone but they drink less.
Acamprosate is best for patients whose drinking is discomfort-driven. They drink to stop feeling restless, anxious, or uncomfortable in their own skin in early sobriety. Acamprosate addresses that post-acute withdrawal directly. Patients on acamprosate report feeling "more normal" instead of feeling "less rewarded."
Where Vivitrol fits
Vivitrol is naltrexone in monthly injection form. The advantage over oral naltrexone is adherence: 28 days of guaranteed coverage per shot. The disadvantage is cost without insurance and the requirement to be opioid-free if the patient also has OUD or takes opioid pain medication.
For AUD patients without opioid use, Vivitrol's induction is simple. No 7-to-10 day window required (that requirement is for OUD treatment, where patients have opioids on board). For most AUD patients, Vivitrol can start immediately at the first appointment if the prescriber stocks it.
Disulfiram and the supervision question
Disulfiram works as long as the patient takes it. Without supervision, most patients stop within weeks. With supervision (a partner who watches them take it daily, a probation officer who confirms compliance, a sober living manager), disulfiram has produced strong results. The supervised studies are some of the best AUD medication outcome data in the literature. Without supervision, results are weaker.
Off-label options
Topiramate has solid randomized trial evidence for AUD, comparable to naltrexone in some studies. It is not FDA-approved for AUD but is widely prescribed off-label, especially for patients with comorbid migraine or epilepsy where it has on-label indications.
Gabapentin has weaker but real evidence, particularly for patients with AUD complicated by anxiety, sleep disturbance, or post-acute withdrawal symptoms. Generic and inexpensive. Used commonly in addiction medicine clinics.
What about Naltrexone for "Sinclair Method"
The Sinclair Method uses oral naltrexone taken before drinking, with the goal of "pharmacological extinction" of the drinking response. There is some research support but it is outside the FDA-approved labeling. Many patients pursue this approach when traditional abstinence-based treatment has not worked. It is one option among several, not a different drug.
The honest take
If you have AUD, you should be on a medication. Pick one based on your drinking pattern (reward-driven vs discomfort-driven), your living situation (supervised dosing available?), and your insurance. Vivitrol for adherence-challenged patients. Acamprosate for post-detox stability. Naltrexone if you want to test the response before committing to an injection. Disulfiram if you have someone to supervise. The wrong choice is "no medication."